A shift in the balance between two lipids – cholesterol and sphingomyelin – makes hybrid epithelial-mesenchymal cancer cells less responsive to certain chemotherapy drugs.
A replication stress–ELF3 axis enables luminal progenitor transformation in BRCA1-deficient breast cancer by reducing genomic instability and promoting progenitor identity.
Kyle Spinler, Michael Hamilton ... Tannishtha Reya
A naturally occurring Musashi2 genetic translocation reported to occur in blast crisis chronic myelogenous leukemia patients can act as an oncogene and drive myeloid leukemia.
Maintaining CDK4/6 inhibition constrains drug‑resistant breast tumors by delaying cell‑cycle entry, and adding CDK2 inhibition further deepens control to guide post‑progression therapy.
Megan E Patton, Sherwin Kelekar ... Sayeepriyadarshini Anakk
Transcriptomic and metabolite analysis reveal sex differences in circulation and excretion of bile acids in a mouse- model of hepatocellular carcinoma (HCC), and the identified female-specific gene profile correlates with better HCC survival.
Using drugs that inhibit enzymes called CDK4/6 and CDK2 extends the G1 phase of the cell cycle and helps to slow the growth of drug-resistant breast cancer.
Genes steadily associated with prognosis define conserved mitotic and immune programs that robustly predict cancer patient survival and therapeutic resistance across tumor types.
Distinct transcriptional subtypes in PPGLs link molecular programs with immune context, providing biomarkers for recurrence risk and therapeutic targeting.
Francine C Cadoná, Thais F Bartelli ... Emmanuel Dias-Neto
Elevated gfDNA supports gastric cancer diagnosis and may guide management when combined with tissue biopsies, and in established cancer, higher gfDNA may predict better outcomes, potentially indicating immune-cell infiltration.
